Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment

Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment

Source: 
CP Wire
snippet: 

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, reported on 4/25/18 new positive magnetic resonance efficacy results showing slowed disease progression in boys with Duchenne muscular dystrophy (DMD) in the MoveDMD trial through 48 weeks of edasalonexent treatment. Both magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) were performed in the Phase 2 MoveDMD trial and open-label extension.